<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4786">
  <stage>Registered</stage>
  <submitdate>9/01/2015</submitdate>
  <approvaldate>9/01/2015</approvaldate>
  <nctid>NCT02343120</nctid>
  <trial_identification>
    <studytitle>Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies</studytitle>
    <scientifictitle>A Phase I, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects With B-Cell Lymphoid Malignancies</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>BGB-3111-AU-003</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Relapsed/Refractory B-cell Malignancies</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BGB-3111

Experimental: BGB-3111 - 


Treatment: drugs: BGB-3111
In the dose-escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.
In the safety, schedule and efficacy expansion part, patients will be assigned to different cohorts based on histology type.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of participants with adverse events</outcome>
      <timepoint>From first dose to within 28 days of last dose of BGB-3111</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the plasma concentration-time curve from time 0 to the time of the last measurable concentration (AUClast)</outcome>
      <timepoint>During first 2 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the plasma concentration-time curve from time 0 to infinity time (AUC8)</outcome>
      <timepoint>During first 2 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum plasma concentration (Cmax)</outcome>
      <timepoint>During first 2 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to reach maximum plasma concentration (tmax)</outcome>
      <timepoint>During first 2 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Terminal elimination half-life (t1/2)</outcome>
      <timepoint>During first 2 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>BTK inhibition activity of BGB-3111 by measurement of free BTK</outcome>
      <timepoint>During first 2 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tumor response</outcome>
      <timepoint>Every 12 weeks from first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Aged = 18 years, voluntarily consented to the study.

          2. WHO classification defined B-lymphoid malignancy, with the exception of Burkitt
             lymphoma/leukemia, plasma cell myeloma, acute lymphoblastic leukemia, lymphoblastic
             lymphoma, and plasmablastic lymphoma.

          3. Requirement for treatment in the opinion of the investigator.

          4. Disease which has relapsed, or is refractory, following at least one line of therapy,
             with no therapy of higher priority available.

          5. ECOG performance status of 0-2.

          6. Adequate hematologic function, as defined by neutrophils = 1.0 x 10^9/L and platelets
             = 50 x 10^9/L; patients with neutrophils &lt; 1.0 x 10^9/L due to marrow infiltration are
             allowed to receive growth factors to bring pre-treatment neutrophils to = 1.0 x
             10^9/L.

          7. Adequate renal function, as defined by creatinine clearance of = 50 ml/min (as
             estimated by the Cockcroft-Gault equation or as measured by nuclear medicine scan or
             24 hour urine collection).

          8. Adequate liver function, as defined by AST and ALT = 3 x ULN, and bilirubin = 1.5 x
             ULN (unless documented Gilbert's syndrome).

          9. INR and APTT = 1.5 x ULN.

         10. Female subjects of childbearing potential and non-sterile males must practice at least
             one of the following methods of birth control with partner(s) throughout the study and
             for 90 days after discontinuing study drug: total abstinence from sexual intercourse,
             double-barrier contraception, IUD or hormonal contraceptive initiated at least 3
             months prior to first dose of study drug.

         11. Male subjects must not donate sperm from initial study drug administration, until 90
             days after drug discontinuation.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Current CNS involvement by disease

          2. Current histologically transformed disease.

          3. Prior BTK inhibitor treatment.

          4. Allogeneic stem cell transplantation within 6 months, or has active GVHD requiring
             ongoing immunosuppression.

          5. Receipt of the following treatment prior to first dose of BGB-3111: corticosteroids
             given with anti-neoplastic intent within 7 days, chemotherapy or radiotherapy within 2
             weeks, monoclonal antibody within 4 weeks.

          6. Not recovered from toxicity of any prior chemotherapy to grade = 1.

          7. History of other active malignancies within 2 years of study entry, with exception of
             (1) adequately treated in-situ carcinoma of cervix; (2) localized basal cell or
             squamous cell carcinoma of skin; (3) previous malignancy confined and treated locally
             (surgery or other modality) with curative intent.

          8. Uncontrolled systemic infection requiring parenteral anti-microbial therapy.

          9. Major surgery in the past 4 weeks.

         10. Known HIV, or active hep B or hep C infection (detected positive by PCR).

         11. Cardiovascular disease resulting in New York Heart Association function status of = 3.

         12. Significant active renal, neurologic, psychiatric, hepatic or endocrinologic disease
             that in the investigator's opinion would adversely impact on his/her participating in
             the study.

         13. Inability to comply with study procedures.

         14. On medications which are CYP3A inhibitors.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>235</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/10/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC,WA</recruitmentstate>
    <hospital>Concord Repatriation General Hospital - Concord</hospital>
    <hospital>Westmead Hospital - Westmead</hospital>
    <hospital>Princess Alexandra Hospital - Brisbane</hospital>
    <hospital>Monash Health - Clayton</hospital>
    <hospital>Austin Health - Heidelberg</hospital>
    <hospital>Peter MacCallum Cancer Centre, East Melbourne - Parkville</hospital>
    <hospital>Melbourne Health - Parkville</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <postcode> - Concord</postcode>
    <postcode> - Westmead</postcode>
    <postcode> - Brisbane</postcode>
    <postcode> - Clayton</postcode>
    <postcode> - Heidelberg</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode> - Parkville</postcode>
    <postcode> - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Busan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Goyang-si</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>BeiGene</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment
      effect of a new drug known as BGB-3111 in patients with B-Cell Lymphoid Malignancies.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02343120</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jason Yang, MD, PhD</name>
      <address>BeiGene</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Eric Hedrick, MD</name>
      <address />
      <phone />
      <fax />
      <email>clinicaltrials@beigene.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>